FDA Approved Drug Now May Be Used In Alcohol Addictions: Research Study

FDA Approved Drug Now May Be Used In Alcohol Addictions: Research Study


  • Post By : Kumar Jeetendra

  • Source: Queensland University of Technology

  • Date: 16 Apr,2016

Alcohol is legal substances that often used and now a day’s number of its common in all restaurants and hotels and its strange that high level of alcoholism is serious medical case.

The World Health Organization estimates that as of 2010 there were 208 million people with alcoholism worldwide (4.1% of the population over 15 years of age). In the United States about 17 million (7%) of adults and 0.7 million (2.8%) of those age 12 to 17 years of age are affected.

Now, Researcher from Queensland University of Technology suggested an already approved drug by FDA, Food and Drug Administration named “pindolol” generally used by AUDs (alcohol use disorders) — acamprosate, naltrexone and disulfiram.

According to researcher,

"In an internationally-significant breakthrough, our study showed pindolol was able to reduce ethanol/alcohol consumption, particularly in relation to binge drinking, a key behaviour observed in human alcohol dependence."

The concern study recently appears in Addiction Biology, the Journal of the Society for the Study of Addiction. "Pindolol is an FDA-approved beta blocker already used to treat high blood pressure and angina," said Mr Patkar.

"Data collected from our study found that pindolol diminishes ethanol intake in animal models of binge-alcohol consumption.

Note: The above story is for information purposes for more information go through original story source.

Story source: Queensland University of Technology

Journal references:

Omkar L. Patkar, Arnauld Belmer, Joan Y. Holgate, Josephine R. Tarren, Masroor R. Shariff, Michael Morgan, Matthew J. Fogarty, Mark C. Bellingham, Selena E. Bartlett, Paul M. Klenowski. The antihypertensive drug pindolol attenuates long-term but not short-term binge-like ethanol consumption in mice. Addiction Biology, 2016; DOI: 10.1111/adb.12359

About Author